Rosuvastatin Calcium Tablets- Newlystar (Ningbo) Medtech Co., Ltd.

Newlystar (Ningbo) Medtech Co., Ltd.

We only export finished medicines. We are a professional trading company, if you must make deal with manufacturer, please find manufacturer directly.
We export to Europe, to Latin American, to Asia, to Africa. We have clients in more than 30 countries.
Each year, we have big deal with a lot manufacturers in China, because the quantity is big, our price is competitive.
And to make our business longer and stable, we only deal with manufacturers with good quality.

We have a quality department dealing with registration dossier and help manufacturers pass higher GMP inspection. We are the best one in China in this issue.

Above are features of Newlystar.
If you want read more information about our company, please go ahead. But usually, offical company introduction, doesn't have many useful information.(That is my personal opinion.)

Newlystar Medtech cooperate with state of the art facilities in China and export medicines to 30+ countries worldwide. Include East Europe, Central and southeast Asia, Latin America, Africa etc. We also contract manufacture for European companies.

Newlystar-Medtech is a well established and professional supplier of Finished Pharmaceutical, Active Pharmaceutical Ingredient(API) and Medical Devices. With a proven track record of passed years, Newlystar-Medtech has been recognized by her customers as a high-quality and reliable supplier not only on products, but also on assistance for audit and improvement of GMP level, quality management system, EHS management system and registration dossier support, etc.
The essence of Newlystar-Medtech's activites, is a commitment to her customers with professional service and high-quality products with effective cost and innovative solutions. All pharmacists work in Newlystar-Medtech like a bridge link the customers and Chinese manufacturers, especially, their professional working is to make the formulation manufacturers who is familiar with Chinese Pharmacopoeia to understand well the international requirement, to ensure the success of customers.
The advantages on professional working and strongly representative base on first-class manufacturing partners in China, enable Newlystar-Medtech to provide her customers with a wide range and high-tech products, best services and capabilities for their actions in tender, distributing and improvement in their national healthcare system. Newlystar-Medtech also dedicates herself to sourcing quality medical products for Chinese market.

Services and capabilities include:
1. Sourcing quality manufacturer
2. Contract manufacturing;
3. Conduct audits to suppliers (pharmaceutical plants);
4. Consultation on audit and improvement of GMP level, quality management system and EHS management system;
5. Regulatory support, registration dossier working;

Newlystar Medtech, your professional one-stop China Souring Partner.

Home>Product>Rosuvastatin Calcium Tablets

Rosuvastatin Calcium Tablets

FOB Price:Get Latest Price >
Min.Order:30000 Box(es)
Payment Terms:L/C , T/T

Favorite

Newlystar (Ningbo) Medtech Co., Ltd.

Business Type:Trader

Country/Region:China

Ddu Verified

HOT Rank

8/10

Product Information

Dosage Form:Tablet
Route of Administration:Oral
Shelf Life:3 years
Storage:Sealed

Description

Product : Rosuvastatin Calcium Tablets

Specification : 5mg, 10mg, 20mg, 40mg

Standard : In - house

Packing : 7’s/blister

Description :

Rosuvastatin calcium is a synthetic lipid-lowering agent for oral administration.

Rosuvastatin calcium Tablets for oral administration contain 5, 10, 20, or 40 mg of rosuvastatin and other inactive ingredients.

Indications and Usage :

1.1 Hyperlipidemia and Mixed Dyslipidemia

ROSUVASTATIN CALCIUM TABLETS is indicated as adjunctive therapy to diet to reduce elevated Total-C, LDL-C, ApoB, nonHDL‑C, and triglycerides and to increase HDL‑C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate.

Pediatric Patients 10 to 17 years of age with Heterozygous Familial Hypercholesterolemia (HeFH)

Adjunct to diet to reduce Total‑C, LDL‑C and ApoB levels in adolescent boys and girls, who are at least one year post-menarche, 10‑17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL‑C > 190 mg/dL or > 160 mg/dL and there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors.

1.2 Hypertriglyceridemia

ROSUVASTATIN CALCIUM TABLETS is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia.

1.3 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia)

ROSUVASTATIN CALCIUM TABLETS is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia).

1.4 Homozygous Familial Hypercholesterolemia

ROSUVASTATIN CALCIUM TABLETS is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL‑C, Total‑C, and ApoB in adult patients with homozygous familial hypercholesterolemia.

1.5 Slowing of the Progression of Atherosclerosis

ROSUVASTATIN CALCIUM TABLETS is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total‑C and LDL‑C to target levels.

1.6 Primary Prevention of Cardiovascular Disease

In individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease based on age ≥ 50 years old in men and ≥ 60 years old in women, hsCRP ≥ 2 mg/L, and the presence of at least one additional cardiovascular disease risk factor such as hypertension, low HDL‑C, smoking, or a family history of premature coronary heart disease, ROSUVASTATIN CALCIUM TABLETS is indicated to:

reduce the risk of stroke

reduce the risk of myocardial infarction

reduce the risk of arterial revascularization procedures

1.7 Limitations of Use

Rosuvastatin Calcium Tablets has not been studied in Fredrickson Type I and V dyslipidemias.